Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:IDYA NASDAQ:MNPR OTCMKTS:NWPHF NASDAQ:PHAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AIDYAIDEAYA Biosciences$24.61-1.3%$23.94$13.45▼$37.80$2.16B0.121.20 million shs1.05 million shsMNPRMonopar Therapeutics$49.22+3.3%$39.33$3.33▼$54.30$303.69M1.238,061 shs22,352 shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/APHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVARAVIVE0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences0.00%-9.39%+1.15%+9.92%-34.30%MNPRMonopar Therapeutics0.00%+11.33%+37.83%+43.83%+1,175.13%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AIDYAIDEAYA Biosciences$24.61-1.3%$23.94$13.45▼$37.80$2.16B0.121.20 million shs1.05 million shsMNPRMonopar Therapeutics$49.22+3.3%$39.33$3.33▼$54.30$303.69M1.238,061 shs22,352 shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/APHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVARAVIVE0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences0.00%-9.39%+1.15%+9.92%-34.30%MNPRMonopar Therapeutics0.00%+11.33%+37.83%+43.83%+1,175.13%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVARAVIVE 0.00N/AN/AN/AIDYAIDEAYA Biosciences 2.81Moderate Buy$42.8574.10% UpsideMNPRMonopar Therapeutics 3.00Buy$71.7545.77% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/APHASPhaseBio Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NWPHF, ARAV, MNPR, PHAS, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025IDYAIDEAYA BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$43.00 ➝ $44.009/9/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $38.009/9/2025IDYAIDEAYA BiosciencesStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$45.009/9/2025IDYAIDEAYA BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/9/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$87.009/8/2025IDYAIDEAYA BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$36.009/4/2025IDYAIDEAYA BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform9/4/2025IDYAIDEAYA BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$41.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.009/4/2025IDYAIDEAYA BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVARAVIVE$9.14MN/AN/AN/AN/AN/AIDYAIDEAYA Biosciences$7M308.12N/AN/A$12.25 per share2.01MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ANWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVARAVIVE-$76.32MN/A0.00∞N/AN/AN/AN/AN/AIDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)NWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ALatest NWPHF, ARAV, MNPR, PHAS, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVARAVIVEN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVARAVIVEN/AN/AN/AIDYAIDEAYA BiosciencesN/A12.3912.39MNPRMonopar TherapeuticsN/A33.9333.93NWPHFNewron PharmaceuticalsN/AN/AN/APHASPhaseBio PharmaceuticalsN/A0.470.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVARAVIVE35.80%IDYAIDEAYA Biosciences98.29%MNPRMonopar Therapeutics1.83%NWPHFNewron PharmaceuticalsN/APHASPhaseBio Pharmaceuticals49.02%Insider OwnershipCompanyInsider OwnershipARAVARAVIVE60.40%IDYAIDEAYA Biosciences2.50%MNPRMonopar Therapeutics20.50%NWPHFNewron PharmaceuticalsN/APHASPhaseBio Pharmaceuticals9.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVARAVIVE20N/AN/ANo DataIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableNWPHF, ARAV, MNPR, PHAS, and IDYA HeadlinesRecent News About These CompaniesPhio Pharma announces strategic initiative to create awareness of the comprehensive INTASYL siRNA portfolioJune 9, 2025 | pharmabiz.comPTicagrelor antidote safely, effectively restores platelet function and treats bleedingApril 1, 2025 | msn.comMedPharm appoints Bill Humphries as new CEOFebruary 6, 2025 | msn.comMedpharm Appoints Chief Executive OfficerFebruary 4, 2025 | contractpharma.comCPhaseBio Pharmaceuticals Inc.October 19, 2024 | thestreet.comPhiladelphia-area life sciences industry nears 900 layoffs since 2022October 11, 2024 | bizjournals.comPhaseBio Pharmaceuticals, Inc. (PHASQ)August 3, 2024 | ca.finance.yahoo.comModified Release Neurology Therapeutics Report 202…February 19, 2024 | pharmiweb.comPVelia Therapeutics Appoints Michael York as Chief Business OfficerDecember 14, 2023 | finance.yahoo.comLeading innovators in GLP-1 analogues for the pharmaceutical industryNovember 6, 2023 | pharmaceutical-technology.comPAlcami Announces CEO TransitionJune 5, 2023 | finance.yahoo.com8-K: PhaseBio Pharmaceuticals IncMay 12, 2023 | marketwatch.comAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsMarch 31, 2023 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finanznachrichten.deBioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finance.yahoo.comCardiomyopathy Medication Market Size and Forecast till 2031March 22, 2023 | marketwatch.comCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries DataFebruary 28, 2023 | marketwatch.comJi Xing obtains global rights to cardiovascular candidate from PhasebioFebruary 9, 2023 | bioworld.comBBankrupt PhaseBio settles with investor-partner, handing off late-stage drugJanuary 18, 2023 | endpts.comESFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio PharmaceuticalsJanuary 17, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Can Identity Security Fuel CrowdStrike’s Next Growth Phase?By Chris Markoch | August 22, 2025A Bull Case for Quantum Computing Stock Is Still AliveBy Gabriel Osorio-Mazilli | September 3, 2025Beyond DIY: Home Depot's Conquest of the Professional MarketBy Jeffrey Neal Johnson | September 10, 2025NWPHF, ARAV, MNPR, PHAS, and IDYA Company DescriptionsARAVIVE NASDAQ:ARAV$0.04 0.00 (0.00%) As of 09/12/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.IDEAYA Biosciences NASDAQ:IDYA$24.61 -0.32 (-1.28%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$24.63 +0.02 (+0.08%) As of 05:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Monopar Therapeutics NASDAQ:MNPR$49.22 +1.55 (+3.25%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$49.38 +0.16 (+0.33%) As of 05:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 09/12/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
